Pathophysiology of portal hypertension

Journal of Physiology and Pharmacology

Volumn 59, Issue SUPPL.2, 2008, Pages 231-238

  Cichoz Lach, Halina ^a   Celinski K ^a   Slomka M ^a   Kasztelan Szczerbinska B ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Ethiology; Pathophysiology; Portal hypertension

Indexed keywords

ENDOTHELIN 1; NITRIC OXIDE; PROSTAGLANDIN DERIVATIVE;

ASCITES; BLOOD VESSEL TONE; CAUSAL ATTRIBUTION; COLLATERAL CIRCULATION; CONFERENCE PAPER; ESOPHAGUS VARICES; HEPATIC ENCEPHALOPATHY; HUMAN; LIVER CIRRHOSIS; LIVER SINUSOID; LIVER VEIN THROMBOSIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; SCHISTOSOMIASIS; STELLATE CELL; STORAGE DISEASE; VASOCONSTRICTION; VASODILATATION;

HUMANS; HYPERTENSION, PORTAL; LIVER CIRCULATION; NITRIC OXIDE; PLASMA VOLUME; VASCULAR RESISTANCE; VASODILATION;

EID: 51449088023     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (30)

1. De Franchis R. Envolving consensus in portal hypertension. Raport of the Baveno IV consensus workshop on methodology of diagnosis and therapy of portal hypertension. J Hepatol 2005; 43: 167-176.
2. Cardenas A, Ginem P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol 2005; 42 (Suppl. 1): S124-133.
3. Simon K. Diagnostyka i leczenie nadciśnienia wrotnego ze szczególnym uwzglȩdnieniem metod endoskopowych. Przegl Epidemiol 2006; 60: 715-724.
4. Bessa X, Callaghan E, Balleste B et al. Applicability of the Rockall score in patients undergoing endoscopic therapy for upper gastrointestinal bleeding. Dig Liv Dis 2006; 38: 12-17.
5. Henderson JM. Surgical treatment of portal hypertension. Ballieres Best Pract Res Clin Gastroenterol 2000; 14: 911-925.
6. Gonciarz Z, Mazur W. Nadciśnienie wrotne. In Gastroenterologia i hepatologia kliniczna, SJ Konturek (eds). Warszawa, PZWL, 2006, pp. 715-725.
7. Tsai MH. Splanchnic and systemic vasodilatation: the patient. J Clin Gastroenterol 2007: 41 (Suppl 3): S266-271.
8. Shah V. Molecular mechanisms of increased intrahepatic resistance in portal hypertension. J Clin Gastroenterol 2007; 41(Suppl 3): S259-261.
9. Gatta A, Bolognesi M, Merkel C. Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis. Mol Aspects Med 2008; 29: 119-129.
10. Malyshev E, Tazi KA, Moreau R, Lebrec D. Discrepant effects of inducible nitric oxide synthase modulation on systemic and splanchnic endothelial nitric oxide synthase activity and expression in cirrhotic rats. J Gastroenterol Hepatol 2007; 22: 2195-2201.
11. Zipprich A. Hemodynamics in the isolated cirrhotic liver. J Clin Gastroenterol 2007; 41 (Suppl 3): S254-258.
12. Watanabe N, Takashimizu S, Nishizaki Y, Kojima S, Kagawa T, Matsuzaki S. An endothelin A receptor antagonist induces dilatation of sinusoidal endothelial fenestrae: implications for endothelin-1 in hepatic microcirculation. J Gastroenterol 2007; 42: 775-782.
13. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 2001; 5: 629-644.
14. Brzozowski T, Konturek PC, Konturek SJ, Brzozowska I, Pawlik T. Role of prostaglandins in gastroprotection and gastric adaptation. J Physiol Pharmacol 2005; 56 (Suppl 5): 33-55.
15. Konturek SJ, Konturek PC, Brzozowski T. Prostaglandins and ulcer healing. J Physiol Pharmacol 2005; 56 (Suppl 5): 5-31.
16. Reeves HL, Friedman SL. Activation of hepatic stellate cells - a key issue in liver fibrosis. Front Biosci 2002; 7: d808-d826.
17. Mallat A. Hepatic stellate cells and intrahepatic modulation of portal pressure. Digestion 1998; 59: 416-419.
18. Chen Y, Wang CP, Lu YY et al. Hepatic stellate cells may be potential effectors of platelet activating factor induced portal hypertension. World J Gastroenterol 2008; 14: 218-223.
19. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10: 459-779.
20. Marra F, Pinzani M. Role of hepatic stellate cells in the pathogenesis of portal hypertension. Nefrologia 2002; 22 (Suppl 5): 34-40.
21. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-581.
22. Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999; 19: 397-410.
23. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999; 19: 359-82.
24. Rockey DC. New concepts in the pathogenesis of portal hypertension: hepatic wounding and stellate cell contractility. Clin Liver Dis 1997; 1: 13-29.
25. Harmanci O, Bayraktar Y. Clinical characteristics of idiopathic portal hypertension. World J Gastroenterol 2007; 13: 1906-1911.
26. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851.
27. Menon KV, Kamath PS. Managing the complications of cirrhosis. Mayo Clin Proc 2000; 75: 501-509.
28. Kwiecień S, Brzozowski T, Konturek PC, Konturek SJ. The role of reactive oxygen species in action of nitric oxide-donors on stress-induced gastric mucosal lesions. J Physiol Pharmacol 2002; 53: 761-773.
29. Konturek SJ, Konturek PC, Brzozowski T. Melatonin in gastroprotection against stress-induced acute gastric lesions and in healing of chronic gastric ulcers. J Physiol Pharmacol 2006; 57 (Suppl 5): 51-66.
30. Petruff CA., Chopra S. Classification of portal hypertension. In Handbook of liver disease. LS Friedman, LS Keeffe EB (eds). Philadelphia, Churchill Livingstone, 2004, pp.264-265.